Menu
Updates in Psoriasis Management 2020 Based on Selected Presentations from Maui Derm 2020 January 25–29, 2020, Maui, Hawaii by Jo Ann LeQuang Ms. Lequang is Owner of LeQ Medical in Angleton, Texas; Director of Scientific Communications at NEMA Research, Inc., in Naples, Florida; and Founding Director of No Baby Blisters in Colorado Springs, Colorado. J
J Clin Aesthet Dermatol. 2020;13(5):48–53 by Paul Macklis, MS; Kevin Adams, BA; Jessica Kaffenberger, MD; Purnima Kumar, BDS MS PhD; Andrew Krispinsky, MD; and Benjamin Kaffenberger, MD Mr. Macklis is with the Ohio State University College of Medicine in Columbus, Ohio. Mr. Adams with with the University of Toledo College of Medicine in Toledo, Ohio.
A message from the Guest Editor and MauiDerm Program Director, George Martin, MD Dear Colleagues: The 2020 edition of the MauiDerm for Dermatologists meeting had a variety of clinical and scientific data presented, but not just at the podium. A wide range of clinically relevant material was also presented in poster format. For those of
J Clin Aesthet Dermatol. 2020;13(5):12–18 by Dharm S. Patel, PhD; Karen A. Veverka, PhD; Jes B. Hansen, PhD; Paul S. Yamauchi, MD; Javier Alonso-Llamazares, MD; and Mark Lebwohl, MD Drs. Patel and Veverka are with LEO Pharma in Madison, New Jersey. Dr. Hansen is with LEO Pharma in Ballerup, Denmark. Dr. Yamauchi is with the
Background. Inverse psoriasis is characterized by erythematous nonscaly plaques in intertriginous regions. Similarly, erythrasma, a superficial infection caused by Corynebacterium minutissimum (C. minutissimum), is also found in skin folds with red-brown lesions, making the distinction between psoriasis and erythrasma difficult.
